financetom
Business
financetom
/
Business
/
Insmed Says FDA Approves Brinsupri for Non-Cystic Fibrosis Bronchiectasis
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Insmed Says FDA Approves Brinsupri for Non-Cystic Fibrosis Bronchiectasis
Aug 12, 2025 9:41 AM

12:20 PM EDT, 08/12/2025 (MT Newswires) -- Insmed ( INSM ) said Tuesday the US Food and Drug Administration has approved Brinsupri to treat non-cystic fibrosis bronchiectasis in adults and children 12 years and above.

Brinsupri is the first and only FDA-approved treatment for NCFB, the company said.

Shares of Insmed ( INSM ) were up over 4% in recent trading.

Price: 117.91, Change: +5.02, Percent Change: +4.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Church & Dwight's Q1 Adjusted Earnings, Net Sales Rise; 2024 Non-GAAP EPS Guidance Revised
Church & Dwight's Q1 Adjusted Earnings, Net Sales Rise; 2024 Non-GAAP EPS Guidance Revised
May 2, 2024
08:40 AM EDT, 05/02/2024 (MT Newswires) -- Church & Dwight ( CHD ) reported Q1 adjusted earnings Thursday of $0.96 per diluted share, up from $0.85 a year earlier. Analysts polled by Capital IQ expected $0.87. Net sales for the quarter ended March 31 were $1.50 billion, compared with $1.43 billion a year earlier. Analysts surveyed by Capital IQ expected...
--Janus Henderson to Acquire National Bank of Kuwait's Private Investments Team
--Janus Henderson to Acquire National Bank of Kuwait's Private Investments Team
May 2, 2024
08:43 AM EDT, 05/02/2024 (MT Newswires) -- Price: 31.63, Change: +0.47, Percent Change: +1.51 ...
Novo Nordisk Lifts Full-Year Sales Outlook as Obesity, Diabetes Drugs Drive First-Quarter Topline Beat
Novo Nordisk Lifts Full-Year Sales Outlook as Obesity, Diabetes Drugs Drive First-Quarter Topline Beat
May 2, 2024
08:39 AM EDT, 05/02/2024 (MT Newswires) -- Novo Nordisk ( NVO ) raised its full-year sales growth outlook on Thursday after the Danish drugmaker's topline topped Wall Street's expectations, buoyed by robust demand for its diabetes and obesity treatments. Sales are now anticipated to grow between 19% and 27% at constant exchange rates, compared with prior projections for an increase...
Novartis to buy radiology drug specialist Mariana for $1 billion
Novartis to buy radiology drug specialist Mariana for $1 billion
May 2, 2024
May 2 (Reuters) - Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. The deal includes up to $750 million of further payments upon achieving certain milestones, it added. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved